Moxifloxacin (MOX) is a broad-spectrum fluoroquinolone antibiotic used in the treatment of various bacterial infections, including acute exacerbation of chronic bronchitis, community-acquired pneumonia, skin and soft tissue infections, complicated…
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, which rapidly spread worldwide and resulted in a pandemic. Efficient and sensitive detection techniques have been devised since the…
Cancer remains a mammoth challenge, accounting for one in every six deaths globally. But aptamers are offering new solutions from reagents to next-gen ADCs. Despite the scale of the…
In this webinar Aptamer’s Chief Scientific Officer, Dr David Bunka, discusses how Optimers can be used for developing cancer research reagents, new therapies and diagnostic tools. Aptamers, initially discovered…
Optimer® binders offer a solution for quick and convenient analysis of small molecule targets, such as drugs, vitamins, or hormones, through affinity-based assays. With a unique discovery process dedicated to small…
Optimer beacons are reagents for simple, solution-based detection and analysis of target concentration. These beacons work by binding to specific analytes in a solution, resulting in a fluorescent…
Affinity binders are the workhorses of assays and methods across the life sciences. From biologics to bioprocessing ligands and research reagents, the requirements for affinity binders vary according to…
Your research is unique. We tailor your Optimer discovery strategy to match, delivering the highest chance of success and the best Optimer performance. Download this booklet to learn how: …
Not all protein-binding aptamers are developed equally. And they shouldn’t be. When developing aptamers to protein targets the ‘how’ is just as important as the ‘what’. The ‘what’ is what…
